Mark A. Socinski

This concluding segment explores the future of EGFR-mutant non-small cell lung cancer (NSCLC) treatment beyond current osimertinib-based therapy.

This segment examines the real-world challenges of ensuring timely access to effective therapies for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

This segment explores treatment sequencing following progression on osimertinib-based therapy for EGFR-mutant non-small cell lung cancer (NSCLC).

This segment examines best practices for monitoring treatment response and evaluating disease progression during osimertinib-based therapy for EGFR-mutant non-small cell lung cancer (NSCLC).

This segment explores the evolving role of circulating tumor DNA (ctDNA) in monitoring treatment response in EGFR-mutant non-small cell lung cancer (NSCLC).

This segment focuses on the real-world management of treatment-related toxicities in EGFR-mutant non-small cell lung cancer (NSCLC).

This segment discusses the clinical impact of transitioning from intravenous to subcutaneous amivantamab in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC).

This segment compares the currently available frontline combination treatment options for EGFR-mutant non-small cell lung cancer (NSCLC), emphasizing the importance of individualized treatment selection.

This segment examines treatment approaches following disease progression in EGFR-mutant non-small cell lung cancer (NSCLC), with a focus on the role of continuing osimertinib beyond progression.

This segment focuses on identifying clinical factors that influence the use of combination therapy for EGFR-mutant non-small cell lung cancer (NSCLC).

This segment explores how treatment decisions for EGFR-mutant non-small cell lung cancer (NSCLC) are increasingly individualized despite the availability of combination frontline therapies.

This introductory segment provides an overview of the evolving treatment landscape for EGFR-mutant non-small cell lung cancer (NSCLC) and establishes the key themes for the discussion.

Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses challenges facing immunotherapy combinations in patients with non–small cell lung cancer (NSCLC).